Anti-Mullerian hormone is associated with extrauterine involvement and stage of disease in patients with endometrial cancer

Basit Öğe Kaydı
dc.contributor.authorDogan, N. U.
dc.contributor.authorKerimoglu, O. S.
dc.contributor.authorKarabagli, P.
dc.contributor.authorPekin, A.
dc.contributor.authorYilmaz, S. A.
dc.contributor.authorIncesu, F.
dc.contributor.authorCelik, C.
dc.date.accessioned2020-03-26T19:00:51Z
dc.date.available2020-03-26T19:00:51Z
dc.date.issued2015
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractOur aim was to evaluate serum levels of anti-Mullerian hormone (AMH) and also immunohistochemical (IHC) staining properties of AMH receptor type II (AMHRII) in patients with endometrial cancer (EC) and a control group. Preoperatively, serum levels of AMH were assessed and AMHRII expression was evaluated by immunohistochemistry in a benign and malignant group. AMH serum levels of the control group and EC patients were comparable. For EC patients, there was no difference with respect to the AMH levels and tumour stage; grade; histological type; deep myometrial invasion; lymphovascular space invasion or lymph node involvement. However, AMH levels in patients with extrauterine involvement were higher than patients with disease confined to the uterus. EC samples were more likely to be stained positive for AMHRII than benign lesions. Also, as the stage of the lesion worsens, the rate of IHC staining of AMHRII decreases. In conclusion, AMHRII is expressed in normal endometrial cells as well as endometrial cancer cells. AMH levels increase in EC, with extrauterine involvement at least in locally advanced disease. Also AMH expression decreases as the disease is staged-up.en_US
dc.description.sponsorshipScientific Research Project Committee of Selcuk University, Konya, TurkeySelcuk Universityen_US
dc.description.sponsorshipThis study was supported by funds supplied by Scientific Research Project Committee of Selcuk University, Konya, Turkey.en_US
dc.identifier.doi10.3109/01443615.2014.941343en_US
dc.identifier.endpage182en_US
dc.identifier.issn0144-3615en_US
dc.identifier.issue2en_US
dc.identifier.pmid25111828en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage178en_US
dc.identifier.urihttps://dx.doi.org/10.3109/01443615.2014.941343
dc.identifier.urihttps://hdl.handle.net/20.500.12395/31847
dc.identifier.volume35en_US
dc.identifier.wosWOS:000347797000017en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherINFORMA HEALTHCAREen_US
dc.relation.ispartofJOURNAL OF OBSTETRICS AND GYNAECOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAnti-Mullerian hormoneen_US
dc.subjectanti-Mullerian hormone receptor type IIen_US
dc.subjectendometrial canceren_US
dc.subjectextrauterine involvementen_US
dc.subjectimmunohistochemical stainingen_US
dc.titleAnti-Mullerian hormone is associated with extrauterine involvement and stage of disease in patients with endometrial canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize